National Cancer Institute Home at the National Institutes of Health |
Please wait while this form is being loaded....
The Applied Research Program Web site is no longer maintained. ARP's former staff have moved to the new Healthcare Delivery Research Program, the Behavioral Research Program, or the Epidemiology & Genomics Research Program, and the content from this Web site is being moved to one of those sites as appropriate. Please update your links and bookmarks!

Economic Burden of Cancer

The economic burden of cancer is the economic cost to the nation associated with expenditures on cancer preventive, screening and treatment services, the economic cost associated with time and effort spent by patients and their families undergoing cancer treatment and the economic cost associated with lost productivity due to cancer-related disability and premature death. One approach to estimating this burden is the Cost-of-Illness study, that uses various national level data sources to obtain estimates of these various components. Our bibliography on cost of illness lists publications that provide Cost-of-Illness estimates for the aggregate (national), annual economic costs of cancer, including costs which are related to direct medical expenditures, lost economic activity due to morbidity and lost economic activity due to premature mortality. These reports also tend to include all types of cancer. These studies may be useful for ascertaining an aggregate, global picture of the economic burden of cancer to the US on an annual basis.

Last Modified: 11 Apr 2014